China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Britain Courts Anthropic Amid US Defense Department Dispute 
NEW YORK, Nov. 21, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) securities between May 11, 2015 and November 8, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/arrowhead-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Arrowhead made false and misleading statements and/or failed to disclose that: (1) its drug candidate ARC-520 was fatal at certain doses; (2) the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) the Company overstated the approval prospects and commercial viability of ARC-520; and (4) as a result of the above, Arrowhead’s public statements were materially false and misleading at all relevant times.
On November 8, 2016, after the close of the market, Arrowhead Pharmaceuticals announced that the United States Food & Drug Administration had decided to place a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. According to the company, the hold stems from deaths at the highest dose of an ongoing non-human primate toxicology study.
If you suffered a loss in Arrowhead you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/arrowhead-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
